Rheumatology
Conference Coverage
Abatacept makes inroads in psoriatic arthritis
WASHINGTON – Abatacept achieved promising results in patients with psoriatic arthritis through 24 weeks of treatment in a placebo-controlled,...
Conference Coverage
Continue DMARDs, biologics in RA surgery patients
WASHINGTON - The perioperative use of disease-modifying antirheumatic drug monotherapy or combined therapy with methotrexate and tumor necrosis...
Conference Coverage
Urate-lowering therapy poses no harm to kidney function
WASHINGTON – Evidence supporting the renal benefits of urate-lowering therapy in patients with hyperuricemia and gout comes from two separate...
Conference Coverage
VIDEO: Celecoxib just as safe as naproxen or ibuprofen in OA and RA
WASHINGTON - Celecoxib conferred a 53% decreased risk of overall mortality upon patients with rheumatoid arthritis when compared with naproxen - a...
Conference Coverage
VIDEO: PRECISION exonerates celecoxib: cardiovascular risk is no worse than that of nonselective NSAIDs
NEW ORLEANS – The cardiovascular safety profile of the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, a selective inhibitor of COX-2, is...
Conference Coverage
Tocilizumab makes big impression in giant cell arteritis treatment
WASHINGTON - Tocilizumab treatment every week or every other week for 52 weeks with a 26-week prednisone taper was superior to a short and long...
Conference Coverage
VIDEO: Cardiac inflammation present in RA patients, but resolves with RA therapy
WASHINGTON - Chronic cardiac inflammation is present in rheumatoid arthritis patients and appears to resolve when they achieve a good clinical...
Conference Coverage
VIDEO: Allopurinol may not raise kidney disease risk in gout
WASHINGTON – Urate-lowering therapy (ULT) with allopurinol does not appear to increase the risk of chronic kidney disease in patients with gout...
Conference Coverage
Genetic markers may predict response to biologics in rheumatoid arthritis
Three gene expression markers appear to predict response to some of the most common and powerful rheumatoid arthritis drugs employed in clinical...
From the Journals
OA progresses equally with new focal partial- or full-thickness cartilage damage
A small, partial-thickness focal cartilage defect in the tibiofemoral joint compartment has the same impact on osteoarthritis disease progression...
Conference Coverage
What good are biosimilars if patients won’t use them?
BOSTON – The only meaningful measure of the success of biosimilar drugs for arthritis is whether patients use them.